Fundamental Analysis of PROTARA THERAPEUTIC INC(NASDAQ:TARA) stock

Fundamental Rating

Overall TARA gets a fundamental rating of 3 out of 10. We evaluated TARA against 588 industry peers in the Biotechnology industry. While TARA has a great health rating, there are worries on its profitability. TARA does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

TARA had negative earnings in the past year.

In the past year TARA has reported a negative cash flow from operations.

In the past 5 years TARA always reported negative net income.

TARA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

TARA has a Return On Assets of -51.20%. This is comparable to the rest of the industry: TARA outperforms 48.63% of its industry peers.

With a decent Return On Equity value of -59.16%, TARA is doing good in the industry, outperforming 61.95% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-51.2%
ROE	-59.16%
ROIC	N/A

ROA(3y)-45.59%

ROA(5y)-73.53%

ROE(3y)-50.98%

ROE(5y)-80.84%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

TARA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for TARA has been increased compared to 1 year ago.

Compared to 5 years ago, TARA has more shares outstanding

TARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

TARA has an Altman-Z score of -2.56. This is a bad value and indicates that TARA is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -2.56, TARA perfoms like the industry average, outperforming 46.42% of the companies in the same industry.

TARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-2.56

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 11.17 indicates that TARA has no problem at all paying its short term obligations.

The Current ratio of TARA (11.17) is better than 82.59% of its industry peers.

TARA has a Quick Ratio of 11.17. This indicates that TARA is financially healthy and has no problem in meeting its short term obligations.

TARA's Quick ratio of 11.17 is amongst the best of the industry. TARA outperforms 82.59% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	11.17
Quick Ratio	11.17

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TARA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.53%, which is quite good.

EPS 1Y (TTM)10.53%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q41.94%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, TARA will show a very strong growth in Earnings Per Share. The EPS will grow by 24.12% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-12.74%

EPS Next 2Y-10%

EPS Next 3Y-0.1%

EPS Next 5Y24.12%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TARA. In the last year negative earnings were reported.

Also next year TARA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-10%

EPS Next 3Y-0.1%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for TARA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PROTARA THERAPEUTIC INC

NASDAQ:TARA (5/3/2024, 7:20:49 PM)

After market: 2.91 0 (0%)

2.91

+0.02 (+0.69%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap33.26M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-51.2%
ROE	-59.16%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	11.17
Quick Ratio	11.17
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)10.53%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-12.74%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

PROTARA THERAPEUTIC INC (TARA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens